Notable Monday Option Activity: BEN, RARE, DBRG

Ultragenyx (RARE) saw 11,756 option contracts trade (≈1.2M underlying shares), about 79.7% of its one‑month average daily volume (1.5M); the $35 call expiring Feb 20, 2026 accounted for 2,300 contracts (~230k shares). DigitalBridge (DBRG) logged 43,794 option contracts (≈4.4M underlying shares), or ~65.6% of its one‑month average daily volume (6.7M), with the $16 call expiring Mar 20, 2026 trading 11,473 contracts (~1.1M shares). The outsized call activity suggests concentrated speculative positioning that could influence individual stock price action and implied volatility in the near term.

Analysis

Market structure: outsized call volumes in RARE (11,756 contracts ≈1.2M shares, ~79.7% ADV) and DBRG (43,794 contracts ≈4.4M shares, ~65.6% ADV) signal concentrated bullish positioning that will force market‑maker delta-hedging into underlying over coming months. Because the heavy strikes are long‑dated ($35 RARE exp 20‑Feb‑2026, $16 DBRG exp 20‑Mar‑2026), this is more directional conviction than short-term gamma; underlying liquidity could be stressed if flows concentrate or if vol moves >30–50% from current levels. Winners are long‑upside holders and shorts of underlying (pushes them to cover); losers are option writers lacking hedges and passive holders caught in short squeezes.

Risk assessment: tail risks include negative R&D outcomes for RARE (binary biotech risk) and asset‑sale / leverage shocks or regulatory moves for DBRG (real‑asset financing), each capable of wiping out >50% of option value within days. Time horizons split: immediate (days) sees delta-hedge flows and IV moves; medium (3–6 months) captures corporate catalysts/earnings; long (12–18 months) will resolve true value signaled by LEAPs. Hidden dependencies: concentrated block buys may be hedge of convertible issuance, M&A arbitrage or structured product placement — not pure retail bullishness — raising reversal risk if position is unwound.

Trade implications: prefer asymmetric, defined‑risk exposure. For DBRG the market is implying meaningful upside optionality — use debit call spreads to capture that with limited bleed; for RARE, treat as event/clinical risk and size smaller with protective puts or verticals. Also consider selling short‑dated IV by building calendar/diagonal spreads (sell 3–6 month call premium, buy 12–15 month) to monetize elevated long‑dated demand while limiting tail gamma.

Contrarian angles: consensus assumes flow = fundamental bullishness; it may instead be tactical (block desks, volatility harvesting) so upside could be crowded and mean‑revert. The market may be overpricing persistent upside — if DBRG fails to announce asset sales or RARE misses pipeline milestones, IV can collapse 40–70% and long LEAP holders will see sharp losses. Historical parallels: large LEAP call blocks preceding unwind (e.g., 2020 retail gamma episodes) produced rapid reversals when catalysts failed; so size defensively and force risk‑managed structures.

Key Decisions for Investors

• Establish a 2.0% NAV position in DBRG via a March 20, 2026 $16/$26 bull call spread (buy 1 Mar‑2026 $16, sell 1 Mar‑2026 $26) to capture upside signaled by heavy call flow; cap max loss at premium paid and plan to trim if DBRG >$26 (realize profits) or cut if DBRG < $10 for more than 5 trading days.
• Establish a 1.0% NAV tactical position in RARE using a Feb 20, 2026 $35/$55 call spread (buy $35, sell $55) sized so max loss = 1% NAV; hedge biotech tail risk by buying a 9–12 month 40–50% OTM put (~0.5% NAV) or close positions if RARE falls >30% from entry within 30 days.
• Deploy a volatility decay trade: for both tickers sell 3–6 month at‑the‑money or slightly OTM calls and buy same‑strike 12–15 month calls (calendar/diagonal) sized to 0.5–1.0% NAV each to monetize long‑dated demand; exit if short‑dated IV rises >60% vs entry or if underlying gaps >20% on catalyst.
• Convertible/arbitrage check: before adding sizeable long LEAP exposure, require issuer‑level due diligence (look for announced convertibles, secondary offerings, asset sale processes) and do not exceed combined options+equity exposure of 4% NAV in a single name.